These five well-known dividend stocks were beaten down in the recent selling but will remain attractive long after the tariff ...

Some on Wall Street now advise selling any rally in U.S. markets. However, these four high-yield dividend stocks are keepers.

Copyright 2025 BBC. All rights reserved. The BBC is not responsible for the content of external sites. Read about our approach to external linking.

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the European Union (EU) as first-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in ...

British drugmaker GSK told Manhattan prosecutors that a former employee told colleagues Pfizer held back positive results until after the 2020 election. But the former employee, who worked at both ...

Pfizer (NYSE:PFE) shares fell on Wednesday after The Wall Street Journal reported that U.S. officials have started an investigation into whether the New York-based pharma giant deliberately ...

A senior GSK scientist, who formerly worked at rival Pfizer, had told GSK colleagues that Pfizer delayed announcing the success of its Covid vaccine in 2020 until after that year’s election.

Now given Pfizer's growing pipeline of new drug launches, I think their revenue will likely outgrow the current consensus - the EPS should follow suit in this case as the firm's smart cost ...

Pfizer (NYSE:PFE) is undervalued, trading well below its historical and sector averages despite strong non-COVID revenue growth and cost optimizations. Its expanding pipeline in oncology, obesity ...

Wide-ranging reforms can build resilience to shocks in the face of uncertainties and help the private sector drive growth. Packaging together broad, economy-wide reforms, spanning areas from ...

However, Pfizer does have challenges ahead. Sales of the company’s Covid-19 products are much less than they were amid the pandemic. Sales of Comirnaty and Paxlovid were about $11 billion in ...

Pfizer has disappointed investors for the past three years, but its low valuation could make it attractive now. Its sales may decline a bit in 2025, but management has been targeting long-term ...